Novaliq Completes Enrollment of Second Phase 3 Study for CyclA...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
HEIDELBERG, Germany and CAMBRIDGE, MA, Aug. 10, 2021 /PRNewswire-AsiaNet/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol(R) water-free technology, today announced the second of two Phase 3 (ESSENCE-2) studies, evaluating the investigational drug C...
Authors: LATEST ASIANET NEWS RELEASES